File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery

TitleMethylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery
Authors
KeywordsColorectal Neoplasms
Methylation
CRC patients
Issue Date2019
PublisherNature Research (part of Springer Nature): Fully open access journals. The Journal's web site is located at http://www.nature.com/srep/index.html
Citation
Scientific Reports, 2019, v. 9, p. article no. 10326 How to Cite?
AbstractWith the increasing incidence and mortality of colorectal cancer (CRC), early and accurate diagnosis is of paramount priority to combat this cancer. Epigenetic alterations such as DNA methylation are innovative biomarkers for CRC, due to their stability, frequency, and accessibility in bodily fluids. In this study, blood samples were prospectively collected from patients before and after operation for CRC for determination of methylated septin 9 (mSEPT9) and compared to carcinoembryonic antigen (CEA). The sensitivity of using mSEPT9 methylation status for diagnosing CRC was significantly higher than using elevated CEA levels (73.2% vs 48.2%; p value < 0.001). The sensitivities of both tests increased with higher tumor staging (P = 0.004 and 0.04 respectively). Combined mSEPT9 and CEA had higher accuracy than single CEA or mSEPT9 (P = 0.009 and 0.532 separately). An increase in the methylation level of mSEPT9 detected in the post-operative samples was associated with a higher mortality rate (15.2% vs 1.8%; P = 0.024) and the presence of metastasis (27.3% vs 7.0%; P = 0.013). mSEPT9 was more sensitive than CEA for diagnosing CRC, and combined mSEPT9 and CEA was more accurate. After curative resection, detection of increased mSEPT9 methylation level may indicate adverse outcomes.
Persistent Identifierhttp://hdl.handle.net/10722/273393
ISSN
2019 Impact Factor: 3.998
2015 SCImago Journal Rankings: 2.073
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorMa, ZY-
dc.contributor.authorLaw, WL-
dc.contributor.authorNg, EKO-
dc.contributor.authorChan, CSY-
dc.contributor.authorLau, KS-
dc.contributor.authorCheng, YY-
dc.contributor.authorShin, VY-
dc.contributor.authorKwong, A-
dc.contributor.authorLeung, WK-
dc.date.accessioned2019-08-06T09:28:06Z-
dc.date.available2019-08-06T09:28:06Z-
dc.date.issued2019-
dc.identifier.citationScientific Reports, 2019, v. 9, p. article no. 10326-
dc.identifier.issn2045-2322-
dc.identifier.urihttp://hdl.handle.net/10722/273393-
dc.description.abstractWith the increasing incidence and mortality of colorectal cancer (CRC), early and accurate diagnosis is of paramount priority to combat this cancer. Epigenetic alterations such as DNA methylation are innovative biomarkers for CRC, due to their stability, frequency, and accessibility in bodily fluids. In this study, blood samples were prospectively collected from patients before and after operation for CRC for determination of methylated septin 9 (mSEPT9) and compared to carcinoembryonic antigen (CEA). The sensitivity of using mSEPT9 methylation status for diagnosing CRC was significantly higher than using elevated CEA levels (73.2% vs 48.2%; p value < 0.001). The sensitivities of both tests increased with higher tumor staging (P = 0.004 and 0.04 respectively). Combined mSEPT9 and CEA had higher accuracy than single CEA or mSEPT9 (P = 0.009 and 0.532 separately). An increase in the methylation level of mSEPT9 detected in the post-operative samples was associated with a higher mortality rate (15.2% vs 1.8%; P = 0.024) and the presence of metastasis (27.3% vs 7.0%; P = 0.013). mSEPT9 was more sensitive than CEA for diagnosing CRC, and combined mSEPT9 and CEA was more accurate. After curative resection, detection of increased mSEPT9 methylation level may indicate adverse outcomes.-
dc.languageeng-
dc.publisherNature Research (part of Springer Nature): Fully open access journals. The Journal's web site is located at http://www.nature.com/srep/index.html-
dc.relation.ispartofScientific Reports-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectColorectal Neoplasms-
dc.subjectMethylation-
dc.subjectCRC patients-
dc.titleMethylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery-
dc.typeArticle-
dc.identifier.emailLaw, WL: lawwl@hkucc.hku.hk-
dc.identifier.emailChan, CSY: sycherry@hkucc.hku.hk-
dc.identifier.emailLau, KS: drrhpcrm@hkucc.hku.hk-
dc.identifier.emailShin, VY: vyshin@hku.hk-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.authorityLaw, WL=rp00436-
dc.identifier.authorityShin, VY=rp02000-
dc.identifier.authorityKwong, A=rp01734-
dc.identifier.authorityLeung, WK=rp01479-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41598-019-46876-4-
dc.identifier.pmid31316143-
dc.identifier.pmcidPMC6637112-
dc.identifier.scopuseid_2-s2.0-85069512216-
dc.identifier.hkuros299645-
dc.identifier.volume9-
dc.identifier.spagearticle no. 10326-
dc.identifier.epagearticle no. 10326-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats